Skip to main content

Published locations for Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma

User login

  • Reset your password
  • /content/pembrolizumab-prolonged-pfs-vs-brentuximab-vedotin-r/r-hodgkin-lymphoma
  • /hematologynews/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab-vedotin-r
  • /internalmedicinenews/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab
  • /oncologypractice/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab-vedotin
  • /jcomjournal/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab-vedotin-r/r
  • /hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab
  • /internalmedicine/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab-vedotin